CERT · Certara, Inc.
$7.11
+3.19% last session
End-of-day data · updated 2026-07-25
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
18.1
Dividend yield
—
Beta
1.46
Avg volume
4M
Employees
2K
2D change
5.63%
5D change
8.21%
10D change
6.37%
30D change
36.79%
60D change
44.15%
MTD change
11.59%
YTD change
-14.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CERT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-12
Latest call per bank · past 12 months
Barclays
Equal-Weight$6.50
-8.6% vs priceMorgan Stanley
Equal-Weight$10.00
+40.6% vs priceUBS
Buy$15.00
+111.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-12 | Craig-Hallum | Maintains | Hold | $10.00 → $8.00 |
| 2026-05-12 | BMO Capital | Maintains | Market Perform | $7.00 → $6.00 |
| 2026-05-12 | Barclays | Maintains | Equal-Weight | $8.00 → $6.50 |
| 2026-05-12 | Stephens & Co. | Maintains | Overweight | $10.00 → $9.00 |
| 2026-05-12 | Morgan Stanley | Maintains | Equal-Weight | $11.00 → $10.00 |
| 2026-05-12 | Baird | Maintains | Neutral | $7.00 → $6.00 |
| 2026-04-13 | Keybanc | Maintains | Overweight | $10.00 → $8.00 |
| 2026-03-06 | Barclays | Downgrade | Overweight → Equal-Weight | $8.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 21.1% above the 50-day MA ($5.87).
- Price vs 200-day MA: Trading 7.9% below the 200-day MA ($7.72).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.02) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($4.48) and high ($13.60).
CERT Price Chart
Loading chart for CERT…
Fundamentals
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
More in Health Information Services
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.